Clinical data point to the potential of PD-1/PD-L1-based ICIs in treating TNBC, despite challenges posed by factors like tumor hypoxia, low PD-L1 expression, and immunosuppressive cells [30]. This evidence concerns the gene PDCD1 and neoplasm.